An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
MK-0941
Placebo
LANTUS insulin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Male or female (of non-childbearing potential) between 18 to 70 years of age
- Diagnosed with Type 2 Diabetes and currently being treated with basal insulin
- Smokers may participate, but they are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules
Exclusion Criteria:
- History of Type 1 diabetes
- Treated with peroxisome proliferator-activated receptor (PPAR) agonists within 12 weeks prior to study start
- History of severe hypoglycemia
- Allergic to insulin
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
MK-0941
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Number of Participants Who Experienced an Adverse Event During the Study
Secondary Outcome Measures
Number of Participants Who Experienced an Adverse Event - Titration Scheme 1
In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis in 10-mg q.a.c. increments on Titration Dose [TD] Days 1 to 4 of the Titration Phase 1 of the study.
Number of Participants Who Experienced an Adverse Event - Titration Scheme 2
Titration Scheme #2 (Titration Phase, Days 1 to 4) was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration.
24-Hour Weighted Mean Blood Glucose Levels (mg/dL) by Treatment Group on Day 7
Measurement of the 24-hour weighted mean blood glucose levels of participants receiving MK-0941 or placebo while on basal insulin on Day 7.
Number of Participants Who Experienced an Adverse Event During the Outpatient Treatment Period
During the Outpatient Treatment Period, participants were followed for an additional 2 weeks while at home.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00511472
Brief Title
An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
Official Title
A Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK-0941 Before Each Meal (q.a.c) in Subjects With Type 2 Diabetes Being Treated With Basal Insulin
Study Type
Interventional
2. Study Status
Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
April 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
A study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-0941 in Type 2 diabetics being treated with basal insulin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
70 (Actual)
8. Arms, Groups, and Interventions
Arm Title
MK-0941
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
MK-0941
Intervention Description
In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose [TD] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.
Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
Intervention Type
Drug
Intervention Name(s)
LANTUS insulin
Other Intervention Name(s)
LANTUS
Intervention Description
LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
Primary Outcome Measure Information:
Title
Number of Participants Who Experienced an Adverse Event During the Study
Time Frame
39 days
Secondary Outcome Measure Information:
Title
Number of Participants Who Experienced an Adverse Event - Titration Scheme 1
Description
In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis in 10-mg q.a.c. increments on Titration Dose [TD] Days 1 to 4 of the Titration Phase 1 of the study.
Time Frame
25 days
Title
Number of Participants Who Experienced an Adverse Event - Titration Scheme 2
Description
Titration Scheme #2 (Titration Phase, Days 1 to 4) was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration.
Time Frame
25 days
Title
24-Hour Weighted Mean Blood Glucose Levels (mg/dL) by Treatment Group on Day 7
Description
Measurement of the 24-hour weighted mean blood glucose levels of participants receiving MK-0941 or placebo while on basal insulin on Day 7.
Time Frame
24 hours
Title
Number of Participants Who Experienced an Adverse Event During the Outpatient Treatment Period
Description
During the Outpatient Treatment Period, participants were followed for an additional 2 weeks while at home.
Time Frame
Outpatient Days 1 to 14
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female (of non-childbearing potential) between 18 to 70 years of age
Diagnosed with Type 2 Diabetes and currently being treated with basal insulin
Smokers may participate, but they are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules
Exclusion Criteria:
History of Type 1 diabetes
Treated with peroxisome proliferator-activated receptor (PPAR) agonists within 12 weeks prior to study start
History of severe hypoglycemia
Allergic to insulin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
We'll reach out to this number within 24 hrs